Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2021
May 04, 2021 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO IBT is conducting a phase III-study (“The Connection Study”) which is the last phase of the clinical development program with the pharmaceutical candidate IBP-9414 containing...
Infant Bacterial Therapeutics utökar The Connection Study och inkluderar spädbarn med en födelsevikt under 750 gram
April 29, 2021 16:00 ET
|
Infant Bacterial Therapeutics AB
Efter granskning av Data Monitoring Committee utökar Infant Bacterial Therapeutics “The Connection Study” till att omfatta för tidigt födda barn med en födelsevikt från 500 g till 1000 g. Data...
Infant Bacterial Therapeutics expands The Connection Study to include infants with a birth weight below 750 grams
April 29, 2021 16:00 ET
|
Infant Bacterial Therapeutics AB
After the Data Monitoring Committees’ review Infant Bacterial Therapeutics expands the enrollment criteria of The Connection Study to include 500 - 1000 gram birth weight premature infants. The...
Infant Bacterial Therapeutics erhåller ytterligare patentskydd i Kina
April 15, 2021 13:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) tillkännager idag att det Kinesiska patentmyndigheten har beslutat utfärda ett godkännande av IBTs patentansökan: “A method of activating lactic acid bacteria”,...
Infant Bacterial Therapeutics receives additional patent protection in China
April 15, 2021 13:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) today announces that the Chinese patent office has issued a decision to grant approval of IBTs patent application entitled: A method of activating lactic acid...
Infant Bacterial Therapeutics publicerar årsredovisning för 2020
April 09, 2021 02:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) publicerar idag årsredovisningen för räkenskapsåret 2020. Årsredovisningen finns tillgänglig på IBTs hemsida ibtherapeutics.com under avsnittet...
Infant Bacterial Therapeutics publishes Annual Report for 2020
April 09, 2021 02:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) has today published the Annual Report for 2020. The report is available on IBT’s website ibtherapeutics.com under the section “Investors & Media –...
Kallelse till årsstämma i Infant Bacterial Therapeutics
April 01, 2021 09:00 ET
|
Infant Bacterial Therapeutics AB
Aktieägarna i Infant Bacterial Therapeutics AB (publ) kallas till årsstämma tisdagen den 4 maj 2021. Mot bakgrund av coronaviruset genomförs årsstämman genom förhandsröstning med stöd av tillfälliga...
Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics
April 01, 2021 09:00 ET
|
Infant Bacterial Therapeutics AB
Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Tuesday, May 4, 2021. In light of the coronavirus, the Annual General Meeting is conducted through...
Infant Bacterial Therapeutics announces that the recruitment to the first stage of the Phase III Connection Study is completed - an update about the clinical development of IBP-9414
February 10, 2021 09:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics (IBT) announces that the company has reached an important milestone after recruiting 300 premature infants to the ongoing clinical Phase III study of IBP-9414. This in...